Navigation Links
Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
Date:2/3/2009

PLATINUM clinical program to evaluate PROMUS(TM) Element(TM) Platinum Chromium Stent

NATICK, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the beginning of patient enrollment in the PLATINUM clinical trial, which is designed to evaluate the Company's PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent. The first U.S. patient was enrolled last week at the Medical Center of the Rockies in Loveland, Colorado by Thomas Downes, M.D. The first Japanese patient was also enrolled last week.

The PLATINUM clinical program will enroll 1,728 patients at 160 sites worldwide. The trial will compare the PROMUS Element Everolimus-Eluting Coronary Stent to the PROMUS(TM) Everolimus-Eluting Coronary Stent. The Company plans to develop additional variations of the Element Stent platform, including next generations of a bare-metal stent and a paclitaxel-eluting TAXUS(R) Element Stent.

The Element Stent platform features a proprietary Platinum Chromium Alloy, designed specifically for coronary stents. This alloy, coupled with a new stent architecture, is designed to enable thinner struts, increased flexibility and a lower profile while improving radial strength, recoil and visibility. In addition, the PROMUS Element Stent System incorporates the new Apex(TM) Dilatation Catheter technology, designed to enhance deliverability to complex lesions.

"We are excited to begin evaluating the everolimus version of our third-generation Element Stent," said Keith Dawkins, M.D., Senior Vice President and Associate Chief Medical Officer for Boston Scientific. "The advanced Platinum Chromium Alloy and new balloon catheter offered in the Element Stent System represent significant improvements. Boston Scientific is the only company to offer interventional cardiologists
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
2. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
3. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
4. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
5. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
6. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
7. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
8. Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting
9. Leading Immunologists Convene in Boston
10. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
11. Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientifics SpyGlass(R) Direct Visualization System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 RnRMarketResearch.com adds Syringes ... report that provides an overview of syringes and ... from in-house databases, secondary and primary research. ... products pipeline spread across 124 pages, talking about ... and 5 figures is now available at ...
(Date:7/31/2015)... According to a new market research ... Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), ... Global Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment ... 2020, at a CAGR of 7.6%.from 2015 to 2020. ... T ables and 37 F ...
(Date:7/31/2015)... July 31, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... its previously announced underwritten public offering of 7,666,667 ... offering price of $11.25 per share. The shares ... shares issued upon the exercise in full by ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
... Share the hope." With these words, Lilly USA, LLC, ... the 2010 Oncology On Canvas: Expressions of a Cancer ... biennial competition invites residents of the United States and Puerto ... members, friends, caregivers and healthcare providers - to express, through ...
... Inc. (Nasdaq: OREX ), a biopharmaceutical company focused ... results for the three months ended September 30, 2009. ... , As of September 30, 2009, Orexigen held ... additional $50.9 million in investment securities, available-for-sale. Together, ...
Cached Medicine Technology:Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 2Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 3Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 4Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 5Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10
(Date:7/31/2015)... ... July 31, 2015 , ... Mullin/Ashley Associates , ... the 2015 Aster Awards national competition for a marketing communications campaign created for ... surrounding communities in Coastal Maryland and Southern Delaware. , A Bronze Award was ...
(Date:7/31/2015)... ... 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company ... , BioViva announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to ... a cure. MaxLife will grant 100% of the money raised to BioViva to help ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports ... , Instead of risking containment — or even destruction — of products, an ...
(Date:7/31/2015)... FL (PRWEB) , ... July 31, 2015 , ... ... patients using the RenovoCath,™ a novel catheter that was developed for targeted delivery ... pancreatic cancer are now being treated at Florida Hospital Tampa with the device ...
(Date:7/31/2015)... ... ... Ticket Down is a reputable source of authentic USA vs. Australia tickets ... the Australia Women's National Team in two separate friendly contests. The first match ... second match will occur in Birmingham, Alabama at Legion Field. These friendly international ...
Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2
... has found that major surgeries and operations could prove deadly ... showed that elderly men with even slightly irregular red blood ... major surgery. ,The study, which examined data from ... to demonstrate that even minor anaemia or polycythemia, when the ...
... the wrappers of the diabetes drug Avandia will soon start ... congestive heart failure . ,Some of the experts, ... that the delay in implementation is an example of industry ... ,GlaxoSmithKline's Avandia has been in use since 1999. The ...
... number of panthers is slowly on the rise . ... estimates of the census figures indicated an increase in the ... to the 2004 wildlife census, there were over 550 panthers ... Park, has the maximum number at 83. At least 15 ...
... Bean will soon be available in the South Asian markets, ... licensing agent for India, Pakistan, Bangladesh and Nepal has inked ... popular character portrayed by Rowan Atkinson to the South Asia ... the television producer of the popular comedy series Mr. Bean. ...
... keep children as safe as possible in cars, leaving parents ... major review of restraint legislation, accident statistics and parent surveys ... graduate to an adult seatbelt without the use of ... or about 11 years old, and that children under 12 ...
... Taking serious note of doctors using advertisements to lure ... Monday asked the state's medical council to take steps ... education and research minister Tikshan Sood said here that ... but also a violation of the Medical Council Act. ...
Cached Medicine News:Health News:Major Surgeries and Operations Could Prove Deadly for Anaemic Older Men 2Health News:Child Car Seat Danger 2
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... The reliable, rugged and easy-to-use solution that's ... is required., ,Symeon's light weight and ... moved into any working position. It can ... And excessive cable "spaghetti syndrome" is minimized ...
... Narkomed 6400 Series anesthesia workstation provides ... technologies are combined to provide true ... user. State of the art computer ... onto a single color touchscreen display ...
... Developed to be used in facilities where ... the latest ventilation and gas delivery technologies ... the ability and the functionality of the ... to create yourself a workplace environment that ...
Medicine Products: